Posted by Michael Wonder on 02 Jun 2020
Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women
2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages
The IQWiG has already examined the advantages and disadvantages of ribociclib succinate in combination with an aromatase inhibitor or fulvestrant for post-menopausal patients with hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer in 2017 and 2019.
Since the assessments were based on ongoing studies, the G-BA had limited its corresponding decisions.
